Aragen Life Sciences Sustainability Profile
Aragen Life Sciences, a prominent player in the biotechnology sector, is headquartered in India and operates extensively across major regions, including North America and Europe. Founded in 2000, the company has established itself as a leader in providing integrated solutions for drug discovery, development, and manufacturing. Aragen's core offerings encompass a wide range of services, including biologics, small molecules, and custom research, distinguished by their commitment to innovation and quality. The company has achieved significant milestones, such as expanding its capabilities in biologics and securing partnerships with leading pharmaceutical firms. With a strong market position, Aragen Life Sciences is recognised for its expertise and reliability, making it a preferred partner for clients seeking comprehensive life science solutions.
DitchCarbon Score
How does Aragen Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aragen Life Sciences's score of 87 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aragen Life Sciences's reported carbon emissions
In 2024, Aragen Life Sciences reported total greenhouse gas emissions of approximately 60,000,000 kg CO2e, comprising 5,972,000 kg CO2e from Scope 1, 34,544,000 kg CO2e from Scope 2, and 40,817,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its carbon footprint, aiming for a 50.4% reduction in absolute Scope 1 and 2 emissions by FY2033, using FY2023 as the baseline. Additionally, Aragen is committed to a 50.4% reduction in absolute Scope 3 emissions within the same timeframe. Long-term goals include achieving net-zero emissions across all scopes by FY2050, with a target to reduce total emissions by 90% from the FY2023 baseline. Aragen's climate commitments align with the Science Based Targets initiative (SBTi) and reflect a strong commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. The company is on track to meet its near-term targets and is actively working towards its long-term goals, which also support the Government of India's commitment to net-zero emissions by 2070.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 10,268,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 25,554,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 | 00,000,000 |
How Carbon Intensive is Aragen Life Sciences's Industry?
How Carbon Intensive is Aragen Life Sciences's Location?
Aragen Life Sciences's Scope 3 Categories Breakdown
Aragen Life Sciences's Scope 3 emissions, which decreased by 26% last year and decreased by approximately 26% since 2023, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 50% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
Aragen Life Sciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aragen Life Sciences has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Anthem Biosciences
Sai Life Sciences
Frequently Asked Questions
Common questions about Aragen Life Sciences's sustainability data and climate commitments